The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin main results of the APPROACH-J study

International Heart Journal

Volumn 55, Issue 1, 2014, Pages 39-47

  Daida, Hiroyuki ^a   Teramoto, Tamio ^b   Kitagawa, Yasuhisa ^c   Matsushita, Yasuyuki ^d   Sugihara, Masahiro ^d  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^d DAIICHI SANKYO CO   (Japan)

Author keywords

Cardiovascular disease; Hypercholesterolemia; Occlusive atherosclerotic complications; Primary prevention

Indexed keywords

AGED; ATHEROSCLEROSIS; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES;

EID: 84893533962     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-002     Document Type: Article

References (42)

1. Asia Pacifi c Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacifi c region. Circulation 2005; 112: 3384-90.
2. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 1-12.
3. Wilhelmsen L. ESC Population Studies Lecture 1996. Cardiovascular monitoring of a city over 30 years. Eur Heart J 1997; 18: 1220-30.
4. Scandinavian Simvas Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
7. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent cardiovascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
8. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
9. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Engl J Med 2005; 352: 1425-35.
10. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
11. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
13. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer, et al. ESC/ EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: S1-44.
14. Hata Y, Mabuchi H, Saito Y, et al. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002; 9: 1-27.
15. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiocardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50. (Review)
16. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72.
17. Haria M, McTavish D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53: 299-336. (Review)
18. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-63.
19. Ito H, Ouchi Y, Ohashi Y, et al. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb 2001; 8: 33-44.
20. The Kyushu Lipid Intervention Study Group. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb 2000; 7: 110-21.
21. Saeki T, Sakuma N, Hayakawa K, et al. Low incidence of cardiac events in statin-administered patients in CAG study. J Atheroscler Thromb 2009; 16: 172-8.
22. Teramoto T, Kitagawa Y, Daida H; APPROACH-J Study group. APPROACH-J study: design, rationale, and baseline data of the affi rmation primary prevention with pravastatin in reduction of occlusive atherosclerotic complications in hypercholesterolemia--Japan study. J Atheroscler Thromb 2011; 18: 1054-61.
23. Wakana A, Yoshimura I, Hamada C. A method for therapeutic dose selection in a phase II clinical trial using contrast statistics. Stat Med 2007; 26: 498-511.
24. Yoshimura I, Wakana A, Hamada C. A performance comparison of maximum contrast methods to detect dose dependency. Drug Inf J 1997; 31: 423-32.
25. Sugihara M. Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score. Pharm Stat 2010; 9: 21-34.
26. Tajima N, Kurata H, Nakaya N, et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008; 199: 455-62.
27. Matsuzaki M, Kita T, Mabuchi H, et al; Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087-95.
28. Kawamori R, Fujita T, Matsuoka H, Umemura S, Saito Y. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. Diabetes Res Clin Pract 2009; 83: 241-8.
29. Tanabe N, Iso H, Okada K, et al. Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events-the JALS-ECC-. Circ J 2010; 74: 1346-56.
30. West of Scotland Coronary Prevention Study Group. Infl uence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
31. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by onstudy lipid levels? Circulation 2002; 105: 1162-9.
32. Teramoto T, Nakaya N, Yokoyama S, Ohashi Y, Mizuno K, Nakamura H. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese. J Atheroscler Thromb 2010; 17: 879-87.
33. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
34. Imamura T, Doi Y, Arima H, et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2009; 40: 382-8.
35. Uchiyama S, Nakaya N, Mizuno K, et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci 2009; 284: 72-6.
36. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA 2012; 307: 1273-83.
37. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
38. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009; 25: 705-16. (Review)
39. Kitagawa Y, Teramoto T, Daida H. Adherence to preferable behavior for lipid control by high-risk dyslipidemic Japanese patients under pravastatin treatment: the APPROACH-J study. J Atheroscler Thromb 2012; 19: 795-805.
40. Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010; 56: 977-86.
41. Japan Atherosclerosis Society eds. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Tokyo, Japan: Japan Atherosclerosis Society; 2012.
42. Peto R, Peto J. Asymptotically effi cient rank invariant test procedures. J R Stat Soc Ser A 1972; 135: 185-207.